← Back to Search

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure (REV-HF Trial)

Phase 2

Waitlist Available

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 weeks

Summary

This trial tests resveratrol, a natural compound, on patients with metabolic and muscle function issues. It aims to see if resveratrol can improve blood flow and oxygen use in muscles, helping them work better and recover faster. Resveratrol is known for its potential to enhance exercise performance.

Eligible Conditions

Heart Failure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Isolated Skeletal Muscle Blood Flow

Change in Oxygen extraction and consumption

Secondary study objectives

Vascular Function by CMR

Side effects data

From 2013 Phase 2 trial • 24 Patients • NCT02114892

25%

Headache

Abdominal pain

Sickness

100%

80%

60%

40%

20%

Study treatment Arm

Resveratrol

Placebo

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: ResveratrolExperimental Treatment2 Interventions

1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.

Group II: PlaceboPlacebo Group2 Interventions

2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Resveratrol

2014

Completed Phase 3

~730